NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 362 filers reported holding NOVOCURE LTD in Q2 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,127,737 | -28.4% | 316,331 | +3.7% | 2.24% | -38.9% |
| Q1 2023 | $18,336,746 | -17.9% | 304,901 | +0.1% | 3.66% | -28.0% |
| Q4 2022 | $22,333,755 | -61.5% | 304,482 | -9.2% | 5.08% | -38.9% |
| Q2 2022 | $58,001,000 | -13.5% | 335,191 | +10.9% | 8.32% | -1.8% |
| Q1 2022 | $67,033,000 | +180.7% | 302,194 | -5.0% | 8.47% | +158.7% |
| Q4 2021 | $23,884,000 | -32.8% | 318,109 | +3.9% | 3.27% | -33.8% |
| Q3 2021 | $35,562,000 | -46.9% | 306,123 | +1.3% | 4.94% | -41.6% |
| Q2 2021 | $67,033,000 | +55.7% | 302,194 | -7.2% | 8.47% | +29.3% |
| Q1 2021 | $43,065,000 | -25.8% | 325,806 | -2.8% | 6.55% | -21.2% |
| Q4 2020 | $58,001,000 | +55.3% | 335,191 | -0.1% | 8.32% | +31.8% |
| Q3 2020 | $37,354,000 | +87.1% | 335,586 | -0.3% | 6.31% | +50.8% |
| Q2 2020 | $19,961,000 | -10.2% | 336,617 | +2.0% | 4.18% | -24.6% |
| Q1 2020 | $22,233,000 | -20.2% | 330,163 | -0.2% | 5.55% | -7.0% |
| Q4 2019 | $27,866,000 | +12.8% | 330,672 | +0.1% | 5.97% | +0.4% |
| Q3 2019 | $24,711,000 | +16.5% | 330,456 | -1.5% | 5.94% | +17.2% |
| Q2 2019 | $21,219,000 | +28.6% | 335,585 | -2.0% | 5.07% | +17.7% |
| Q1 2019 | $16,496,000 | +21.6% | 342,455 | -15.5% | 4.31% | +4.3% |
| Q4 2018 | $13,562,000 | -36.8% | 405,066 | -1.1% | 4.13% | -17.8% |
| Q3 2018 | $21,463,000 | +65.3% | 409,606 | -1.3% | 5.02% | +43.7% |
| Q2 2018 | $12,987,000 | +47.4% | 414,929 | +2.7% | 3.50% | +44.7% |
| Q1 2018 | $8,808,000 | +11.7% | 404,052 | +3.5% | 2.42% | +10.7% |
| Q4 2017 | $7,888,000 | +7.9% | 390,473 | +6.1% | 2.18% | -1.3% |
| Q3 2017 | $7,308,000 | +14.1% | 368,167 | -0.6% | 2.21% | +8.1% |
| Q2 2017 | $6,407,000 | +335.6% | 370,335 | +104.0% | 2.04% | +332.1% |
| Q1 2017 | $1,471,000 | -4.3% | 181,561 | -7.3% | 0.47% | -11.8% |
| Q4 2016 | $1,537,000 | +27.7% | 195,848 | +39.0% | 0.54% | +23.8% |
| Q3 2016 | $1,204,000 | +24.0% | 140,941 | +69.4% | 0.43% | +24.1% |
| Q2 2016 | $971,000 | -19.8% | 83,190 | -0.5% | 0.35% | -20.7% |
| Q1 2016 | $1,210,000 | +5.9% | 83,590 | +63.5% | 0.44% | +3.0% |
| Q4 2015 | $1,143,000 | – | 51,140 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |